

Table S1 Search strategy for each database

Database	Search Strategy
PubMed	((“Neuroblastoma”[Mesh] OR “Neuroblastoma”[Text Word] OR “neuroblastoma” OR “neural crest tumor” OR “neuroblastic tumor” OR “childhood cancer” OR “pediatric cancer” OR “neuroblastic tumor”) AND (“Surgical Margins”[Mesh] OR “positive surgical margin” OR “surgical resection” OR “resection margin” OR “margin status” OR “incomplete resection” OR “margin involvement” OR “negative margin” OR “R0 resection” OR “positive margin”) AND (“Survival”[Mesh] OR “Overall Survival” OR “Event-Free Survival” OR “EFS” OR “prognosis” OR “recurrence” OR “local recurrence” OR “metastasis” OR “disease-free survival” OR “long-term survival”))
Scopus	TITLE-ABS-KEY(“neuroblastoma” OR “neural crest tumor” OR “neuroblastic tumor” OR “pediatric cancer” OR “childhood cancer”) AND TITLE-ABS-KEY(“surgical margin” OR “positive surgical margin” OR “incomplete resection” OR “resection margin” OR “margin involvement” OR “negative margin” OR “R0 resection” OR “positive margin”) AND TITLE-ABS-KEY(“overall survival” OR “event-free survival” OR “EFS” OR “prognosis” OR “recurrence” OR “local recurrence” OR “metastasis” OR “disease-free survival” OR “long-term survival”)
Embase	(‘neuroblastoma’/exp OR ‘neuroblastoma’ OR ‘neural crest tumor’ OR ‘neuroblastic tumor’ OR ‘childhood cancer’ OR ‘pediatric cancer’) AND (‘surgical margin’/exp OR ‘positive surgical margin’ OR ‘surgical resection’ OR ‘resection margin’ OR ‘margin status’ OR ‘incomplete resection’ OR ‘R0 resection’ OR ‘positive margin’) AND (‘overall survival’/exp OR ‘event-free survival’ OR ‘EFS’ OR ‘prognosis’ OR ‘recurrence’ OR ‘local recurrence’ OR ‘metastasis’ OR ‘disease-free survival’ OR ‘long-term survival’)
Cochrane Library	((“Neuroblastoma”[MeSH] OR “Neuroblastoma”[Text Word] OR “neuroblastoma” OR “neural crest tumor” OR “neuroblastic tumor” OR “childhood cancer” OR “pediatric cancer” OR “neuroblastic tumor”) AND (“Surgical Margins”[MeSH] OR “positive surgical margin” OR “surgical resection” OR “resection margin” OR “margin status” OR “incomplete resection” OR “margin involvement” OR “negative margin” OR “R0 resection” OR “positive margin”) AND (“Survival”[MeSH] OR “Overall Survival” OR “Event-Free Survival” OR “EFS” OR “prognosis” OR “recurrence” OR “local recurrence” OR “metastasis” OR “disease-free survival” OR “long-term survival”))
Web of Science	TS=(“neuroblastoma” OR “neural crest tumor” OR “neuroblastic tumor” OR “childhood cancer” OR “pediatric cancer”) AND TS=(“surgical margin” OR “positive surgical margin” OR “surgical resection” OR “resection margin” OR “margin status” OR “incomplete resection” OR “margin involvement” OR “negative margin” OR “R0 resection” OR “positive margin”) AND TS=(“overall survival” OR “event-free survival” OR “EFS” OR “prognosis” OR “recurrence” OR “local recurrence” OR “metastasis” OR “disease-free survival” OR “long-term survival”)

**Table S2** Risk of bias and quality assessment of included studies

Author & year	Study design	Selection (max ★4)	Comparability (max ★2)	Outcome (max ★3)	Total (max ★9)	Overall quality
Cooke-Barber <i>et al.</i> , 2021 (30)	Retrospective cohort	★★★ (3/4)	★ (1/2)	★★ (2/3)	6/9	Moderate
Dove <i>et al.</i> , 2018 (25)	Retrospective cohort	★★ (2/4)	★ (1/2)	★★ (2/3)	5/9	Moderate
Fischer <i>et al.</i> , 2017 (20)	Retrospective cohort	★★★ (3/4)	★ (1/2)	★★ (2/3)	6/9	Moderate
Ferris <i>et al.</i> , 2017 (29)	Retrospective cohort	★★★ (3/4)	★ (1/2)	★★ (2/3)	6/9	Moderate
Holmes <i>et al.</i> , 2020 (19)	Prospective cohort	★★★★ (4/4)	★ (1/2)	★★ (2/3)	7/9	High
He <i>et al.</i> , 2024 (33)	Retrospective cohort	★★★ (3/4)	★ (1/2)	★★ (2/3)	6/9	Moderate
Johnsen <i>et al.</i> , 2019 (4)	Retrospective cohort	★★ (2/4)	★ (1/2)	★★ (2/3)	5/9	Moderate
Jazmati <i>et al.</i> , 2022 (26)	Prospective registry	★★★ (3/4)	★★ (2/2)	★★ (2/3)	7/9	High
Jang <i>et al.</i> , 2024 (23)	Retrospective cohort	★★ (2/4)	★ (1/2)	★★ (2/3)	5/9	Moderate
Lv <i>et al.</i> , 2022 (27)	Retrospective cohort	★★★ (3/4)	★ (1/2)	★★ (2/3)	6/9	Moderate
Lee <i>et al.</i> , 2023 (32)	Retrospective cohort	★★ (2/4)	★ (1/2)	★★ (2/3)	5/9	Moderate
Liu <i>et al.</i> , 2020 (31)	Prospective phase III	Adapt Cochrane tool*	–	–	–	Good**
Murphy <i>et al.</i> , 2016 (24)	Retrospective cohort	★★ (2/4)	★ (1/2)	★★ (2/3)	5/9	Moderate
Simon <i>et al.</i> , 2013 (12)	Prospective cohort	★★★ (3/4)	★★ (2/2)	★★ (2/3)	7/9	High
Shirota <i>et al.</i> , 2017 (18)	Retrospective cohort	★★★ (3/4)	★ (1/2)	★★ (2/3)	6/9	Moderate
Schäfer <i>et al.</i> , 2023 (22)	Retrospective cohort	★★ (2/4)	★ (1/2)	★ (1/3)	4/9	Moderate/Low
von Allmen <i>et al.</i> , 2017 (17)	Retrospective cohort	★★★ (3/4)	★ (1/2)	★★ (2/3)	6/9	Moderate
van der Steeg <i>et al.</i> , 2023 (28)	Retrospective cohort	★★ (2/4)	★★ (2/2)	★★ (2/3)	6/9	Moderate
Zhou <i>et al.</i> , 2018 (21)	Retrospective cohort	★★ (2/4)	★ (1/2)	★★ (2/3)	5/9	Moderate

\*For prospective clinical trials (e.g., Liu *et al.*, 2020), the Cochrane Risk of Bias Tool is more appropriate (domains: random sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, etc.). Studies with final “Good” or “High” rating are those scoring 7 or above on NOS or demonstrating low risk of bias in the Cochrane tool. These star (★) allocations are illustrative; you should adapt them to your actual assessment.